Agenus Shifts Focus to ROBBIN Trial and Secures $85M Financing

Biotech firm Agenus announced a strategic shift, prioritizing the Phase 3 ROBBIN trial over its BATTMAN study. The company secured an initial $85 million through private placement with potential for additional funds via warrants. This move led to a significant surge in stock price.

By Shuning Zhao Tue, July 14, 2026 at 5:17 PM GMT+3 4 min read · Yahoo Finance · July 14, 2026, 14:17 UTC

Agenus Shifts Focus to ROBBIN Trial and Secures $85M Financing

Tickers: $AGEN

Topics: Agenus financing announcement Phase 3 trial stock price movement

Read the full article at Yahoo Finance

More World news

Apple to Update HomeView Software Following Feedback on Voice Command Limitations The Verge · November 12, 2026, 16:53 UTC
Endeavour Mining Shares Drop Following Production Warning at Mana Gold Mine Seeking Alpha · November 12, 2026, 16:48 UTC
Stellantis CEO Warns of Multi-Billion Euro Impact from Chip Shortages and Raw Material Costs Seeking Alpha · November 12, 2026, 16:44 UTC
UBS Upgrades Rivian to Buy Rating Amid R2 Potential Motley Fool · November 12, 2026, 16:45 UTC
Stifel Downgrades EVgo to Hold Amid Weakening Growth Outlook Seeking Alpha · November 12, 2026, 16:41 UTC
Rowan Digital Infrastructure Secures Over $1.5 Billion in New Financing Seeking Alpha · November 12, 2026, 16:42 UTC
CAE Reports Q2 2027 Results with Increased EPS Guidance and Strong Defense Growth Motley Fool · November 12, 2026, 16:39 UTC
Alvotech Reports Q3 2026 Financial Results Amid Manufacturing Recovery Motley Fool · November 12, 2026, 16:39 UTC
Jacobs Solutions Declares Quarterly Dividend of $0.36 Per Share Seeking Alpha · November 12, 2026, 16:39 UTC
SOLV Energy Raises Revenue Guidance Following Record Q3 Project Execution Seeking Alpha · November 12, 2026, 16:40 UTC